Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise in shrinking breast cancer before surgery

NCT ID NCT04647487

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called LY3484356 in 87 postmenopausal women with early-stage, hormone-receptor-positive breast cancer. The goal was to see if the drug is safe and how it affects cancer cells before the participants had surgery. The study lasted up to 2.5 months and measured changes in estrogen receptor levels and cancer cell growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Barts Cancer Institute

    London, London City, EC1A 7BE, United Kingdom

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Helios Kliniken Schwerin

    Schwerin, Mecklenburg-Vorpommern, 19049, Germany

  • Hospital Clinic I Provincial

    Barcelona, 08036, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007, Spain

  • Hospital Madrid Norte Sanchinarro

    Madrid, 28050, Spain

  • Hôpital René Huguenin

    Saint-Cloud, Hauts-de-Seine, 92210, France

  • Institut Jules Bordet

    Brussel - Capital, 1070, Belgium

  • Klinikum der Universitaet Muenchen

    München, 80336, Germany

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Northwestern Memorial Hosptial

    Chicago, Illinois, 60611, United States

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee, 37203, United States

  • The Royal Cornwall Hospital

    Truro, Cornwall, TR1 3LJ, United Kingdom

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, 3000, Belgium

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

  • Universitätsklinikum Erlangen

    Erlangen, Bavaria, 91054, Germany

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Winship Cancer Center Emory University

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.